LABORATORY OF MOLECULAR IMMUNOPHARMACOLOGY

Scientific direction

The main current research focus of the laboratory is the development of probiotics based on combinations of spore-forming probiotic bacteria and bacteriocins.Together with colleagues from TRIZ Biopharma Innovations LLC., we are developing dynamic drugs based on self-organizing supramolecular structures with anticancer (MoLRx), antiviral (Albuvir), and antimicrobial properties. The research also focuses on composite pharmacophores derived from known drugs for new applications (Diavenol/Dipasol).

In addition, the development of antiseptics based on atomic hydrogen and devices for their production should be among the main developments of the laboratory.

STAFF

Artur Martynov – head of the Laboratory, Pharm.D., Ph.D., D.Hab., Professor;
Olena Grishyna, MD, PhD, leader researcher (head of clinical division);
Romanova Helen, BD, PhD, leader researcher, (head of immunology division)
Bomko Tatyana, BD, PhD, leader researcher (head of preclinical research division)
Nosalskaya Tatyana, Vet.D.,PhD, leader researcher
Knysh Oksana, M.D.,PhD, D. Hab, leader researcher
Batrak Helen, Pharm.D., PhD, senior researcher
Manuilov Michail, PhD., senior researcher
Sidorenko Tatyana., senior researcher
Igumnova Nataly, senior researcher
Menkus Helen, researcher

Olena Grishyna
MD, Ph.D., leader researcher (head of clinical division)

Romanova Helen
BD, Ph.D., leader researcher,(head of immunology division)

Bomko Tatyana
BD, Ph.D., leader researcher (head of preclinical research division)

Nosalskaya Tatyana
Vet.D.,PhD, leader researcher

Knysh Oksana
M.D.,PhD, D. Hab, leader researcher

Batrak Helen
Pharm.D, Ph.D., senior researcher

Manuilov Michailo
PhD.,senior researcher

Sidorenko Tatyana
senior researcher

Research projects

"Study of the stress factors influence on the antagonistic properties of spore-forming probiotic bacteria"

Laboratory and clinical department of molecular immunopharmacology

Our Partners

Farber's Center for Academic Success LLC, (New-York, USA)
TRIZ Biopharma Innovation, Edison, NJ, USA)
National University of Pharmacy,dpt. of Pharmacognosy and Nutriciology(Kharkov, Ukraine)
Kharkiv City Multidisciplinary Hospital №18

Last Publications

Martynov, A., Didenko, G., Farber, B., Farber, S., & Cruts, O. (2018). The anticancer activity of antisense micro RNA (fRNA) in combination with the lectin from Bacillus subtilis B‐7025. Journal of Pharmacy and Pharmacology, 70(6), 732-739
Bomko, T. V., Nosalskaya, T. N., Kabluchko, T. V., Lisnyak, Y. V., & Martynov, A. V. (2017). Immunotropic aspect of the Bacillus coagulans probiotic action. Journal of Pharmacy and Pharmacology, 69(8), 1033-1040.
Martynov, A., & Knysh, O. (2023). HPLC-pharmaceutical Analysis of Lantibiotic Nisin in the Industrial Samples Including Expired Sample. Methods Objects Chem Anal, 18(2), 87-91.
Knysh, O. V., & Martynov, A. V. (2020). Potentiation of the antimicrobial effect of Lactobacillus reuteri DSM 17938 cell-free extracts by ascorbic acid. Medical perspectives, 25(1), 17-24.
Knysh, O. V., Martynov, A. V., Pokhyl, S. I., & Skliar, N. I. (2023). The behavior of the Bacillus probiotic species under conditions of co-cultivation. Modern medical technology, (4), 59-69.
Knysh, O., & Martynov, A. (2023). Nisin: prerequisites and prospects for application in the medical field. Galician medical journal, 30(1), E202316-E202316.
Knysh, O. V., Martynov, A. V., & Osolodchenko, T. P. (2024). Inhibitory potential of probiotic spore formers grown as mono-and mix-cultures under conditions of different nutrient availability. Modern medical technology, 16(4), 310-317.
Martynov, A., Farber, B., & Katz, A. (2025). Phosphodiesterase Inhibition and Immunotropic Activity of Dipyridamole Dynamic Derivatives. Current Issues in Molecular Biology, 47(4), 214.
Martynov, A., Farber, B., & Farber, S. (2011). Quasi-life self-organizing systems: based on ensembles of succinylated derivatives of interferon-gamma. Current medicinal chemistry, 18(22), 3431-3436.
Lisnyak, Y., Martynov, A., & Farber, B. (2024). Molecular dynamics simulation of the interactions of antimicrobial peptides with phospholipids of the inner membrane of gram-negative bacteria. International Journal of Computational Biology and Drug Design, 16(1), 42-55.
Martynov, A., Lisnyak, Y., & Farber, B. (2023). Interactions between Antimicrobial Peptides and Targets Responsible for their Nephrotoxic Action: Molecular Dynamics Simulations. Current Drug Safety.
Martynov, A., Farber, B., Bomko, T., Beckles, D. L., & Kleyn, I. (2024). Molecular Modeling, Synthesis, and Antihyperglycemic Activity of the New Benzimidazole Derivatives–Imidazoline Receptor Agonists. Drug Design, Development and Therapy, 1035-1052.
Martynov, A., Farber, B., & Farber, S. S. (2011). A method useable in clinics for significantly increasing the effectiveness of treating patients with malignant tumors. European Journal of Internal Medicine, 22, S29.
Martynov, A., Bomko, T., Nosalskaya, T., Farber, B., & Brek, O. (2020). Non-Classical Effects of the cAMP Accumulation Activators In Vivo. Advanced Pharmaceutical Bulletin, 10(3), 477.
Farber, B., Martynov, A., & Kleyn, I. (2018). Creation of new medical drugs based on TRIZ and computer mathematical modeling. Annals of Mechnikov's Institute, (4), 15-34.
Martynov, A. V., Farber, B. S., Farber, S. B., & Kabluchko, T. V. (2015). Synthesis of the ensembles from succinylated interleukin-2 derivatives and their biological activity in vitro. ScienceRise, 11(4 (16)), 25-30.
Knysh, O. V., & Martynov, A. V. (2020). Potentiation of the antimicrobial effect of Lactobacillus reuteri DSM 17938 cell-free extracts by ascorbic acid. Medical perspectives, 25(1), 17-24.
Martynov, A. V., & Smelyanskaya, M. V. (2005). Antiproliferative properties of chemically modified recombinant IFN-α2b. Journal of interferon & cytokine research, 25(7), 414-417.